PARSIPPANY — Ferring Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved the company’s new state-of-the-art drug product manufacturing hub located at 100 Interpace Parkway. The facility will support the production of ADSTILADRIN® (nadofaragene firadenovec-vncg), a groundbreaking intravesical non-replicating gene therapy for high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
The FDA’s approval expands Ferring’s U.S. manufacturing capabilities and triggers the final $200 million payment from Royalty Pharma under a financing agreement established in 2023.
“This expansion and diversification of our manufacturing footprint will further ensure a stable and sustainable supply of ADSTILADRIN to meet the anticipated growth in global demand,” said Armin Metzger, Executive Vice President and Chief Technical Operations Officer at Ferring Pharmaceuticals. “The FDA approval of our new manufacturing facility represents our unwavering dedication to delivering high-quality, innovative therapies at scale.”
Located at Ferring’s U.S. campus in Parsippany, the newly approved 12,000-square-foot facility boasts a cutting-edge manufacturing suite equipped with modern, specialized technology. Reflecting Ferring’s strong commitment to sustainability, the site integrates renewable energy solutions, including waste heat recovery systems and solar energy.
ADSTILADRIN, approved by the FDA for patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors, represents a significant advancement in the treatment of bladder cancer — the sixth most commonly diagnosed cancer in the United States.
“ADSTILADRIN has transformed the treatment landscape for BCG-unresponsive bladder cancer patients and drives Ferring’s continued growth in uro-oncology,” said Bipin Dalmia, Global Head of Uro-Oncology and Urology Franchise for Ferring. “The FDA’s approval of this additional manufacturing site is a testament to our commitment to make ADSTILADRIN globally available to every bladder cancer patient who needs it.”
The new Parsippany site brings Ferring’s ADSTILADRIN manufacturing network to three facilities worldwide, strengthening its ability to meet growing demand and continuing its mission to bring life-changing therapies to patients.
For more information about Ferring Pharmaceuticals and its groundbreaking work, visit ferringusa.com.
